Skip to main content
Log in

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

  • Review article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Various tumours, classically specified as either neuroendocrine or non-neuroendocrine, contain high numbers of somatostatin receptors, which enable in vivo localization of the primary tumour and its metastases by scintigraphy with the radiolabelled somatostatin analogue octreotide. In addition granulomas and autoimmune processes can be visualized because of local accumulation of somatostatin receptor-positive activated mononuclear leucocytes. In many instances a positive scintigram predicts a favourable response to treatment with octreotide. It is tempting to speculate that octreotide labelled with an appropriate radionuclide might be used in cancer therapy. The successful application of radiolabelled octreotide in scintigraphy indicates the possible usefulness of other radiolabelled peptides, either native peptides or derivatives of these, in, for example, nuclear oncology. The small size of these peptides, e.g. bombesin and substance P, is of the utmost importance for a relatively fast blood clearance, thus leading to low background radioactivity. In this way peptides are powerful alternatives to (fragments of) monoclonal antibodies, the application of which to scintigraphic localization of specific cell surface antigen-bearing tumours is plagued by slow blood clearance and, hence, high background levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reubi JC, Maurer R. Autoradiographic mapping of somatostatin receptors in the rat CNS and pituitary. Neuroscience 1985;15:1183–1193.

    Google Scholar 

  2. Patel YC, Amherdt M, Orci L. Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding sites on islets. Science 1982;217:1155–1156.

    Google Scholar 

  3. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989;264:949–953.

    Google Scholar 

  4. Yamada Y, Post SR, Wang K, Tagr HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA 1992;89:251–255.

    Google Scholar 

  5. Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell G, Seino S. Somatostatin receptors; an expanding gene family: cloning and functional characterization of human SSTR 3, a protein coupled to adenylyl cyclase. Mol Endocrinol 1992;6:2136–2142.

    Google Scholar 

  6. O'Carroll A-M, Lolait SJ, Konig M, Mahan LC. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol Pharmacol 1992;42:939–946.

    Google Scholar 

  7. Bruno Jf, Xu Y, Song J, Berelowitz M. Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc Natl Acad Sci USA 1992;89:11151–11155.

    Google Scholar 

  8. Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993;16:34–39.

    Google Scholar 

  9. Koper JW, Markstein R, Kohler C, Kwekkeboom DJ, Avezaat CJJ, Lamberts SWJ, Reubi JC. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab 1992;74:543–547.

    Google Scholar 

  10. Brazeau P. Somatostatin: a peptide with unexpected physiologic activities. Am J Med 1986;81 Suppl 613:8–13.

    Google Scholar 

  11. Lamberts SWJ, Krenning EP, Reubi J-C. The role of somatostatin and its analogs in the diagnosis and treatment of tumours. Endocr Rev 1991;12:450–482.

    CAS  PubMed  Google Scholar 

  12. Reubi JC, Krenning EP, Lamberts SWJ, Kvols L. In vitro detection of somatostatin receptors in human tumours. Metabolism 1992;41(9):104–110.

    Google Scholar 

  13. Reubi JC, Laissue J, Krenning EP, Lamberts SWJ. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implication. J Steroid Biochem Mol Biol 1992;43:27–35.

    Article  CAS  PubMed  Google Scholar 

  14. Pearse AGE, Polak JM, Heath CM. Polypeptide hormone production by ‘carcinoid’ apudomas and their relevant cytochemistry. Virchows Arch [B] 1974;16:95–109.

    Google Scholar 

  15. Reubi JC, Maurer R, Klijn JGM, Stefanko SZ, Foekens JA, Blaauw G, Blankenstein MA, Lamberts SWJ. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 1986;63:433–438.

    CAS  PubMed  Google Scholar 

  16. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SWJ. Distribution and biochemical characterization of somatostatin receptors in tumours of the human central nervous system. Cancer Res 1987;47:5758–5765.

    CAS  PubMed  Google Scholar 

  17. Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ, Laissue J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF-receptors. Int J Cancer 1990;46:416–420.

    Google Scholar 

  18. Reubi JC, Waser B, Sheppard M, Macaulay V. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF receptors. Int J Cancer 1990;45:269–274.

    CAS  PubMed  Google Scholar 

  19. Reubi JC, Waser B, Vanhagen M, Lamberts SWJ, Krenning EP, Gebbers JO, Laissue JA. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992;50:895–900.

    CAS  PubMed  Google Scholar 

  20. Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992;103:1207–1214.

    CAS  PubMed  Google Scholar 

  21. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L, Lameris IS, Lamberts SWJ. Localization of endocrine related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1:242–245.

    Google Scholar 

  22. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooy PPM, Reubi JC, Klijn JGM, Visser TJ, Docter R, Lamberts SWJ. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabelling, purification, biological activity and in vivo applications in animals. J Nucl Med 1990;31:1501–1509.

    CAS  PubMed  Google Scholar 

  23. Lamberts SWJ, Hofland LJ, van Koetsveld PM, Reubi JC, Bruining HA, Bakker WH, Krenning EP. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumours. Consequences with regard to diagnosis, localisation and therapy. J Clin Endocrinol Metab 1990;71:566–574.

    Google Scholar 

  24. Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in the localization of endocrine tumours. N Engl J Med 1990;323:1246–1249.

    Google Scholar 

  25. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Splinter TAW, Kho GS, Lamberts SWJ. Radioiodinated somatostatin analog scintigraphy in small-cell lung cancer. J Nucl Med 1991;32:1845–1848.

    Google Scholar 

  26. Kwekkeboom DJ, Hoff AM, Lamberts SWJ, Oei HY, Krenning EP. Somatostatin analogue scintigraphy: a simple and sensitive method for the in vivo visualization of Merkel cell tumours and their metastases. Arch Dermatol 1992;128:818–821.

    Google Scholar 

  27. Krenning EP, Kwekkeboom DJ, Oei HY, Reubi JC, van Hagen PM, Kooij PPM, Reijs AEM, Lamberts SWJ. Somatostatin receptor imaging of endocrine gastrointestinal tumours. Schweiz Med Wochenschr 1992;122:634–637.

    Google Scholar 

  28. Bakker WH, Krenning EP, Breeman WAP, Kooij PPM, Reubi J-C, Koper JW, de Jong M, Lameris JS, Visser TJ, Lamberts SWJ. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism and binding to somatostatin receptor-positive tumours in man. J Nucl Med 1991;32:1184–1189.

    Google Scholar 

  29. Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, Oei HY, de Jong M, Reubi J-C, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, van Hagen PM, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with [123In-DTPA-D-PHE1]-octreotide in man: metabolism, dosimetry and comparison with [111I-Tyr-3-]-octreotide. J Nucl Med 1992;33:652–658.

    CAS  PubMed  Google Scholar 

  30. Bakker WH, Alberts R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP. [111-In-DTPA-D-PHE1]-Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabelling and in vitro validation. Life Sci 1991;49:1583–1591.

    Article  CAS  PubMed  Google Scholar 

  31. Bakker WH, Krenning EP, Reubi J-C, Breeman WAP, Seytono-Han B, de Jong M, Kooij PPM, Bruns C, van Hagen PM, Marbach P, Visser TJ, Pless J, Lamberts SWJ. In vivo application of [111-In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumours in rats. Life Sci 1991;49:1593–1601.

    Google Scholar 

  32. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. ICRP publication 53, Oxford: Pergamon 1988.

    Google Scholar 

  33. Scicchitano R, Dazin P, Bienenstock J, Payan DG, Stanisz AM. Distribution of somatostatin receptors on murine spleen and Peyer's patch T and B lymphocytes. Brain Behav Immun 1987:1:173–183.

    Google Scholar 

  34. Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989;68:844–850.

    Google Scholar 

  35. Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, Sara R, Bonino C, Lunghi F. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204–090). J Clin Endocrinol Metab 1991;73:850–856.

    Google Scholar 

  36. Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB, Wass JAH, Besser GM. Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin Endocrinol 1992;36:147–150.

    Google Scholar 

  37. de Bruin TWA, Kwekkeboom DJ, Van 't Verlaat JW, Reubi JC, Krenning EP, Lamberts SWJ, Croughs RIM. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro. J Clin Endocrinol Metab 1992;75:1310–1317.

    Google Scholar 

  38. Maton PM, O'Dorisio TM, Howe BA. Effect of a long-acting somatostatin analogue (SMS 201–995) in patients with pancreatic cholera. N Engl J Med 1985;312:17–21.

    Google Scholar 

  39. Wood SM, Kraenzlin ME, Adrian TE, Bloom SR. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue SMS 201–995: symptomatic and peptide responses. Gut 1985;26:438–444.

    Google Scholar 

  40. Moertel CG. An odyssey in the land of small tumours. J Clin Oncol 1987;5:1503–1522.

    Google Scholar 

  41. Kwekkeboom DJ, Van Urk H, Pauw KH, Lamberts SWJ, Kooij PPM, Hoogma R, Krenning EP. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993 (in press).

  42. Som PM, Sacher M, Stollman AL, Biller HF, Lawson W. Common tumours of the parapharyngeal space: refined imaging diagnosis. Radiology 1988;169:81–85.

    Google Scholar 

  43. Grufferman S, Gillman MW, Pasternak LR, Peterson CL, Young WG Jr. Familial carotid body tumours: case report and epidemiologic review. Cancer 1980;46:2116–2122.

    Google Scholar 

  44. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, Bruining HA, Mulder AH, Oei HY, Krenning EP. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993 (in press).

  45. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM, Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993;20:283–292.

    Google Scholar 

  46. Becker W, Marienhagen J, Scheubel R, Schrell U, Buchfelder M, Bakker WA, Wolf F. In-vivo localization of somatostatin receptors with I-123-Tyr-3-octreotide. Eur J Nucl Med 1992;19:737.

    Google Scholar 

  47. Bomanji J, Mather S, Ur E, Grossman A, Besser GM, Britton KE. Imaging somatostatin receptor-positive neoplasms with 123I Tyr3-octreotide (TOCT) and 111In [DTPA-D-Phe1]-octreotide (DOCT) somatostatin analogues. J Nucl Med 1992;33:914.

    Google Scholar 

  48. Pauwels S, Jamar F, Leners N, Fiasse R. Indium-111-pentatreotide scintigraphy in detection of primary, recurrent and metastatic gastro-entero-pancreatic (GEP) endocrine tumours. J Nucl Med 1992;33:976.

    Google Scholar 

  49. Van Dongen A, Verhoeff NPLG, Bemelman F, Van Royen EA. Somatostatin receptor imaging with 111In-pentatreotide for whole body studies and high resolution brain SPECT. Eur J Nucl Med 1992;19:679.

    Google Scholar 

  50. Ivancevic V, Nauck C, Sandrock D, Kögler A, Munz DL, Creutzfeldt W, Emrich D. Somatostatin receptor scintigraphy with 111In-pentatreotide in gastroenteropancreatic endocrine tumours (GEP). Eur J Nucl Med 1992;19:736.

    Google Scholar 

  51. Joseph K, Stapp J, Reinecke J, Höffken H, Benning R, Neuhaus C, Trautmann ME, Schwerk WB, Arnold R. Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren. Dtsch Med Wochenschr 1992;117:1025–1028.

    Google Scholar 

  52. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991;64:567–573.

    Google Scholar 

  53. Reubi JC, Horisberger U, Lang W, Koper JW, Braakman R, Lamberts SWJ. Coincidence of EGF receptors and Somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989;134;337–344.

    Google Scholar 

  54. Lamberts SWJ, Koper JW, Reubi JC, Krenning EP. Endocrine aspects of the diagnosis and treatment of primary brain tumours. Clin Endocrinol 1992;37:1–10.

    Google Scholar 

  55. Foekens JA, Portengen H, van Putten WLJ, Trapman AMAC, Reubi JC, Alexieva-Figuch J, Klijn JGM. Prognostic value of receptors for insulin-like growth factor 1, somatostatin and epidermal growth factor in human breast cancer. Cancer 1989;49:7002–7009.

    Google Scholar 

  56. Bhatena SJ, Louie J, Schechter GP, Redman RS, Wahl L, Recant L. Identification of human mononuclear leucocytes bearing receptors for somatostatin and glucagon. Diabetes 1981;30:127–131.

    Google Scholar 

  57. van Hagen PM, Krenning EP, Reubi JC, Mulder AH, Bakker WH, Oei HY, Löwenberg B, Lamberts SWJ. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol 1993;83:75–79.

    Google Scholar 

  58. Reubi JC, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res 1992;52:6074–6078.

    Google Scholar 

  59. Reubi JC, Modigliani E, Calmettes C, Kvols L, Krenning EP, Lamberts SWJ. In vitro and in vivo identification of somatostatin receptors in medullary thyroid carcinomas, phaeochromocytomas and paragangliomas. In: Calmettes C, Guliana JM, eds. Medullary thyroid carcinomas. London: John Libbey Eurotext Ltd; 1991;211:85–87.

    Google Scholar 

  60. Krenning EP, Oei HY, Kooij PPM, Wijngaarde R, Lamberts SWJ, Wiersinga WM, Prummel MF, Royen EA van, Poublon RML, Hennemann G. Thyroid and orbital radiolabelled somatostatin accumulation in Graves' disease and Graves' ophthalmopathy. J Nucl Med 1992;33:894.

    Google Scholar 

  61. Chang TC, Kao SCS, Huang KM. Octreotide and Graves' ophthalmopathy and myxoedema. Br Med J 1992;304:158.

    Google Scholar 

  62. Matucci C, Marabini S. Somatostatin treatment for pain in rheumatoid arthritis: a double blind versus placebo study in knee involvement. Med Sci Res 1988;16:223–234.

    Google Scholar 

  63. Hoefnagel CA. The clinical use of 131 I-meta-iodobenzyl-guanidine (MIBG) for the diagnosis and treatment of neural crest tumours. Thesis, University of Amsterdam, 1989.

  64. Hoefnagel CA. Radionuclide therapy revisited. Eur J Nucl Med 1991;18:408–431.

    Google Scholar 

  65. Goldenberg DM, Wlodkowski TJ, Sharkey RM, Silberstein EB, Serafini AN, Garty II, van Heertum RL, Higginbotham Ford EA, Kotler JA, Balasubramanian N, Swayne LC, Hansen HJ, Pinsky CM. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 1993;34:61–71.

    Google Scholar 

  66. Kendall-Taylor P, Chatterjee S, White MC, Harris MM, Davidson K, Besser GM, Wass JAH. Octreotide. Lancet 1989;11:859–860.

    Google Scholar 

  67. Ørskov H, Christensen SE, Weeke J, Kaal A, Harris AGEffects of antibodies against octreotide in two patients with acromegaly. Clin Endocrinol 1991;34:395–398.

    Google Scholar 

  68. Kwekkeboom DJ, Assies J, Hofland LJ, Reubi JC, Lamberts SWJ, Krenning EP. A case of antibody formation against octreotide visualized with 111In-octreotide scintigraphy. Clin Endocrinol 1993 (in press).

  69. Sloan DA, Schwartz RW, Kenady DE. Surgical therapy for endocrine tumours of abdominal origin. Curr Opin Oncol 1993;5:100–109.

    Google Scholar 

  70. Kafity AA, Wray DA, Martin EW, Thurston MO, Olsen J, Hinkle GH, Mekhjian HS, O'Dorisio MS, O'Dorisio TM. Novel clinical application of [125I-Tyr3]-octreotide. Fourth international congress on hormones and cancer; Amsterdam, 1991;abstr. 218

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krenning, E.P., Kwekkeboom, D.J., Bakker, W.H. et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20, 716–731 (1993). https://doi.org/10.1007/BF00181765

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00181765

Key words

Navigation